Albany Molecular Research Current Assets

Albany Molecular Research posts a current assets of $400M as of June 2017. That compares with $260M in the prior-year period — up 57.4% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Albany Molecular Research's current assets was $260M. The latest reading is $400M — a 57.4% year-over-year increase (period ending June 2017). Use the history and growth charts on this page for a longer lookback.

Current Assets is one piece of Albany Molecular Research's financial statement story. At $400M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for AMRI's current assets usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Albany Molecular Research's other metric pages and overview cover the third.